ATE237693T1 - Rekombinante foamy-virus-vektoren zur medizinischen und diagnostischen verwendung und verfahren zur herstellung rekombinanter foamy- virus-vektoren - Google Patents

Rekombinante foamy-virus-vektoren zur medizinischen und diagnostischen verwendung und verfahren zur herstellung rekombinanter foamy- virus-vektoren

Info

Publication number
ATE237693T1
ATE237693T1 AT94107918T AT94107918T ATE237693T1 AT E237693 T1 ATE237693 T1 AT E237693T1 AT 94107918 T AT94107918 T AT 94107918T AT 94107918 T AT94107918 T AT 94107918T AT E237693 T1 ATE237693 T1 AT E237693T1
Authority
AT
Austria
Prior art keywords
foamy virus
virus vectors
recombinant foamy
medical
diagnostic use
Prior art date
Application number
AT94107918T
Other languages
English (en)
Inventor
Meulen Volker Prof Dr Ter
Axel Dr Rethwilm
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of ATE237693T1 publication Critical patent/ATE237693T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
    • C12N2740/17022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/17011—Spumavirus, e.g. chimpanzee foamy virus
    • C12N2740/17041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/17043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/80—Vectors comprising a special translation-regulating system from vertebrates
    • C12N2840/85—Vectors comprising a special translation-regulating system from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
AT94107918T 1993-06-03 1994-05-24 Rekombinante foamy-virus-vektoren zur medizinischen und diagnostischen verwendung und verfahren zur herstellung rekombinanter foamy- virus-vektoren ATE237693T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4318387A DE4318387A1 (de) 1993-06-03 1993-06-03 Rekombinante Foamy Virus Vektoren für medizinische und diagnostische Anwendungen sowie Verfahren zur Herstellung von rekombinanten Foamy Virus Vektoren

Publications (1)

Publication Number Publication Date
ATE237693T1 true ATE237693T1 (de) 2003-05-15

Family

ID=6489499

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94107918T ATE237693T1 (de) 1993-06-03 1994-05-24 Rekombinante foamy-virus-vektoren zur medizinischen und diagnostischen verwendung und verfahren zur herstellung rekombinanter foamy- virus-vektoren

Country Status (10)

Country Link
US (1) US5646032A (de)
EP (1) EP0632129B1 (de)
JP (2) JPH06343477A (de)
AT (1) ATE237693T1 (de)
CA (1) CA2124769C (de)
DE (2) DE4318387A1 (de)
DK (1) DK0632129T3 (de)
ES (1) ES2196014T3 (de)
PT (1) PT632129E (de)
SI (1) SI0632129T1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2707091B1 (fr) 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
FR2727429B1 (fr) * 1994-11-30 1997-11-28 Haguenauer Odile Cohen Lignees d'encapsidation et vecteurs d'expression pour la transcomplementation de vecteurs retroviraux defectifs
DE19503082A1 (de) * 1995-02-01 1996-08-08 Univ Ludwigs Albert Gegenstand und Verfahren zur bevorzugt transienten Expression und möglichen Translation spezifischer RNA im cytoplasmatischen Bereich höherer eukaryontischer Zellen
US5888767A (en) * 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
CA2279669A1 (en) * 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acid processing components for therapeutic and diagnostic uses
US6492165B1 (en) 1997-02-12 2002-12-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Retrovirus isolated from humans
US5882912A (en) * 1997-02-12 1999-03-16 Center For Disease Control And Prevention Retrovirus isolated from humans
JP3954151B2 (ja) * 1997-03-14 2007-08-08 トランスジエヌ・エス・アー フォーミーウイルスエンベロープタンパク質の発現
WO2000024876A2 (en) 1998-10-27 2000-05-04 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Spumavirus isolated from humans
DE19858441C2 (de) * 1998-12-17 2001-02-15 Deutsches Krebsforsch FV-Vektoren zur Expression von Fremdgenen in Säugern und deren Verwendung
US6333194B1 (en) * 1999-01-19 2001-12-25 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
US6800475B1 (en) 1999-06-14 2004-10-05 The United States Of America As Represented By The Department Of Health And Human Services Isolation of a human retrovirus
US20050244429A1 (en) * 2002-06-27 2005-11-03 Thomas Folks Live replicating spumavirus vector
AU2003268531A1 (en) 2002-09-06 2004-03-29 University Of South Florida Materials and methods for treatment of allergic diseases
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
EP1727556A2 (de) * 2004-02-17 2006-12-06 University Of South Florida Material und methoden zur behandlung von entzündlichen erkrankungen und zellproliferationsstörungen
US20090202488A1 (en) * 2004-06-04 2009-08-13 Deutsches Krebsforschungczentrum Use Of The Foamy Virus Bet Protein For Inactivating APOBEC
EP2051585A4 (de) * 2006-04-28 2010-06-02 Univ South Florida Materialien und verfahren zur unterdrückung von entzündungen durch hemmung des vorhof-rezeptors für natriuretische peptide
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US11970707B2 (en) * 2017-09-18 2024-04-30 Children's Hospital Medical Center Strong insulator and uses thereof in gene delivery

Also Published As

Publication number Publication date
ES2196014T3 (es) 2003-12-16
DE69432500D1 (de) 2003-05-22
JP2007082562A (ja) 2007-04-05
PT632129E (pt) 2003-08-29
CA2124769C (en) 2007-07-10
DK0632129T3 (da) 2003-08-04
DE69432500T2 (de) 2003-11-20
JPH06343477A (ja) 1994-12-20
DE4318387A1 (de) 1994-12-08
EP0632129B1 (de) 2003-04-16
EP0632129A1 (de) 1995-01-04
US5646032A (en) 1997-07-08
SI0632129T1 (en) 2003-08-31
CA2124769A1 (en) 1994-12-04

Similar Documents

Publication Publication Date Title
DE69432500D1 (de) Rekombinante Foamy-Virus-Vektoren zur medizinischen und diagnostischen Verwendung und Verfahren zur Herstellung rekombinanter Foamy-Virus-Vektoren
NO963358D0 (no) Vertsvektor-system til anvendelse i genterapi
NO173741C (no) DNA-sekvens for modifisert protein C, vektor inneholdende denne, patte-dyrceller transfektert med vektorer, og fremgangsmaate for fremstilling av nevnte protein
ATE78293T1 (de) Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
CA2321964A1 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus
EP0330191A3 (de) CD40 kodierende DNA
ATE213020T1 (de) Klonierung und expression von biologisch aktiver alpha-galaktosidase a
ATE196507T1 (de) Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
DE69828193D1 (de) Hyaluronan synthase gen und seine verwendung
ATE93272T1 (de) Expression von protein c.
ES8802162A1 (es) Un procedimiento para la preparacion de una levadura trans- formada con un plasmido recombinante insertado con el gen del virus de la hepatitis b.
EP0275204A3 (de) Herstellung des Fibroblast-Wachstumsfaktors
WO1998055639A3 (fr) Vecteurs adenoviraux recombinants comprenant une sequence d'epissage
CA2215328A1 (en) Novel human cytomegalovirus dna sequences
CA2326401A1 (en) Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress
EP0294469A4 (de) Impfstoffe und diagnosetest für haemophilus influenzae.
EP0242220A3 (en) Gene expression system
ATE100495T1 (de) Rekombinantes marek-krankheitsvirus, verfahren zu seiner herstellung, und vakzine.
AU3379693A (en) Vaccines and diagnostic assays for haemophilus influenzae
AU4334193A (en) Infectious bovine rhinotracheitis virus mutants and vaccines
NZ242707A (en) Nucleotide sequence and polypeptide of mareks disease virus and vaccine containing the polypeptide
EP0247145A4 (de) Vielfach amplifizierbare vektoren für hohe expression exogener dns.
Mulcahy et al. [56] Use of rous sarcoma viral genome to express human fibroblast interferon
ATE122097T1 (de) Expressionsvektor und verfahren zur regulierbaren herstellung von proteinen in eukaryonten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0632129

Country of ref document: EP

REN Ceased due to non-payment of the annual fee